# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001571049-17-003520
Filing Date
2017-04-12
Accepted
2017-04-12 16:34:14
Documents
5
Period of Report
2017-05-30
Effectiveness Date
2017-04-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE PROXY STATEMENT | t1700099-def14a.htm | DEF 14A | 625698
2 | GRAPHIC | t1700099_pc1.jpg | GRAPHIC | 315824
3 | GRAPHIC | t1700099_pc2.jpg | GRAPHIC | 250598
4 | GRAPHIC | t1700099_pc3.jpg | GRAPHIC | 240881
5 | GRAPHIC | t1700099_pc4.jpg | GRAPHIC | 198966
| Complete submission text file | 0001571049-17-003520.txt |  | 1996620

Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-50626 | Film No.: 17758312
SIC: 2834 Pharmaceutical Preparations